156 related articles for article (PubMed ID: 28457754)
1. Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging.
Niida A; Sasaki S; Yonemori K; Sameshima T; Yaguchi M; Asami T; Sakamoto K; Kamaura M
Bioorg Med Chem Lett; 2017 Jun; 27(12):2757-2761. PubMed ID: 28457754
[TBL] [Abstract][Full Text] [Related]
2. K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology.
Sakamoto K; Kamada Y; Sameshima T; Yaguchi M; Niida A; Sasaki S; Miwa M; Ohkubo S; Sakamoto JI; Kamaura M; Cho N; Tani A
Biochem Biophys Res Commun; 2017 Mar; 484(3):605-611. PubMed ID: 28153726
[TBL] [Abstract][Full Text] [Related]
3. Crystal Structure of a Human K-Ras G12D Mutant in Complex with GDP and the Cyclic Inhibitory Peptide KRpep-2d.
Sogabe S; Kamada Y; Miwa M; Niida A; Sameshima T; Kamaura M; Yonemori K; Sasaki S; Sakamoto JI; Sakamoto K
ACS Med Chem Lett; 2017 Jul; 8(7):732-736. PubMed ID: 28740607
[TBL] [Abstract][Full Text] [Related]
4. Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo.
Sakamoto K; Masutani T; Hirokawa T
Sci Rep; 2020 Dec; 10(1):21671. PubMed ID: 33303890
[TBL] [Abstract][Full Text] [Related]
5. Substituted tetrahydroisoquinolines: synthesis, characterization, antitumor activity and other biological properties.
Capilla AS; Soucek R; Grau L; Romero M; Rubio-Martínez J; Caignard DH; Pujol MD
Eur J Med Chem; 2018 Feb; 145():51-63. PubMed ID: 29324343
[TBL] [Abstract][Full Text] [Related]
6. Discovery, optimization and biological activity evaluation of genipin derivatives as potential KRAS G12D inhibitors.
Sun R; Hu Y; Liu X; Lin Y; Lv D; Li W; Fu L; Jiang F
Bioorg Chem; 2024 Jul; 148():107460. PubMed ID: 38781668
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and biological evaluation of new Myo-inositol derivatives as potential RAS inhibitors.
Hussain J; Chhabria D; Kirubakaran S
Bioorg Med Chem Lett; 2020 Aug; 30(16):127290. PubMed ID: 32631512
[TBL] [Abstract][Full Text] [Related]
8. Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
Wang X; Allen S; Blake JF; Bowcut V; Briere DM; Calinisan A; Dahlke JR; Fell JB; Fischer JP; Gunn RJ; Hallin J; Laguer J; Lawson JD; Medwid J; Newhouse B; Nguyen P; O'Leary JM; Olson P; Pajk S; Rahbaek L; Rodriguez M; Smith CR; Tang TP; Thomas NC; Vanderpool D; Vigers GP; Christensen JG; Marx MA
J Med Chem; 2022 Feb; 65(4):3123-3133. PubMed ID: 34889605
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel substituted thiourea derivatives as potential anticancer agents for NSCLC by blocking K-Ras protein-effectors interactions.
Zhang Y; Meng X; Tang H; Cheng M; Yang F; Xu W
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):344-353. PubMed ID: 31851852
[TBL] [Abstract][Full Text] [Related]
10. Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS
Xu LL; Li CC; An LY; Dai Z; Chen XY; You QD; Hu C; Di B
Eur J Med Chem; 2020 Jan; 185():111844. PubMed ID: 31706640
[TBL] [Abstract][Full Text] [Related]
11. A PDX model combined with CD-DST assay to evaluate the antitumor properties of KRpep-2d and oxaliplatin in KRAS (G12D) mutant colorectal cancer.
Li W; Chen W; Wang J; Zhao G; Chen L; Wan Y; Luo Q; Li W; Huang H; Li W; Li W; Yang Y; Chen D; Su Q
Heliyon; 2022 Dec; 8(12):e12518. PubMed ID: 36590511
[TBL] [Abstract][Full Text] [Related]
12. Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
Qin M; Wang T; Xu B; Ma Z; Jiang N; Xie H; Gong P; Zhao Y
Eur J Med Chem; 2015 Nov; 104():115-26. PubMed ID: 26451770
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel quinazoline-based covalent inhibitors of KRAS G12C with various cysteine-targeting warheads as potential anticancer agents.
Li L; Zhao H; Liao H; Chen J; Liu J; Chen J
Bioorg Chem; 2021 May; 110():104825. PubMed ID: 33774492
[TBL] [Abstract][Full Text] [Related]
14. K-Ras
Feng H; Zhang Y; Bos PH; Chambers JM; Dupont MM; Stockwell BR
Biochemistry; 2019 May; 58(21):2542-2554. PubMed ID: 31042025
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship study of syringolin A as a potential anticancer agent.
Chiba T; Matsuda A; Ichikawa S
Bioorg Med Chem Lett; 2015 Nov; 25(21):4872-4877. PubMed ID: 26231162
[TBL] [Abstract][Full Text] [Related]
16. Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones.
Jose B; Oniki Y; Kato T; Nishino N; Sumida Y; Yoshida M
Bioorg Med Chem Lett; 2004 Nov; 14(21):5343-6. PubMed ID: 15454224
[TBL] [Abstract][Full Text] [Related]
17. Selective cytotoxicity of a bicyclic Ras inhibitor in cancer cells expressing K-Ras(G13D).
Palmioli A; Sacco E; Airoldi C; Di Nicolantonio F; D'Urzo A; Shirasawa S; Sasazuki T; Di Domizio A; De Gioia L; Martegani E; Bardelli A; Peri F; Vanoni M
Biochem Biophys Res Commun; 2009 Sep; 386(4):593-7. PubMed ID: 19540195
[TBL] [Abstract][Full Text] [Related]
18. The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors.
Sakamoto K; Lin B; Nunomura K; Izawa T; Nakagawa S
Sci Rep; 2022 May; 12(1):8121. PubMed ID: 35581303
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic G12D mutation alters local conformations and dynamics of K-Ras.
Vatansever S; Erman B; Gümüş ZH
Sci Rep; 2019 Aug; 9(1):11730. PubMed ID: 31409810
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a Direct Ras Inhibitor by Screening a Combinatorial Library of Cell-Permeable Bicyclic Peptides.
Trinh TB; Upadhyaya P; Qian Z; Pei D
ACS Comb Sci; 2016 Jan; 18(1):75-85. PubMed ID: 26645887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
